![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Efficacy and Safety of Entecavir Versus Adefovir in Chronic Hepatitis B Patients with Evidence of Hepatic Decompensation: Week 96 Results
|
|
|
Reported by Jules Levin
21st APASL, Asian Liver Socity Meeting, Bangkok, Feb 17-20, 2011
Hugo Cheinquer1, Maria Raptopoulou-Gigi2, Shiv Kumar Sarin3, Tawesak Tanwandee4, Nancy Leung5, Cheng-Yuan Peng6, Robert P Myers7, Robert S Brown Jr8, Lennox Jeffers9, Naoky Tsai10, Jolanta Bialkowska11,
Shijie Tang12, Yi-Cheng Chen13, Suzanne Beebe12, Elizabeth Cooney12, Yun-Fan Liaw13
1Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil; 2Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece; 3Department of Gastroenterology, G. B. Pant Hospital, New Delhi, India;
4Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; 5Alice Ho Miu Ling Nethersole Hospital, Hong Kong, China; 6China Medical University Hospital, Taichung, Taiwan; 7Liver Unit, University of Calgary, Alberta, Canada;
8Center for Liver Disease and Transplantation, Columbia University Medical Center, New York, USA; 9Miami VA Medical Center, Miami, Florida, USA; 10John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii;
11Department of Infectious Diseases, Medical University, Lodz, Poland; 12Research and Development, Bristol-Myers Squibb Company, Wallingford, USA; 13Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan
![apasl1.gif](../images/022411/022411-5/apasl1.gif)
![apasl2.gif](../images/022411/022411-5/apasl2.gif)
![apasl3.gif](../images/022411/022411-5/apasl3.gif)
![apasl4.gif](../images/022411/022411-5/apasl4.gif)
![apasl5.gif](../images/022411/022411-5/apasl5.gif)
![apasl6.gif](../images/022411/022411-5/apasl6.gif)
![apasl7.gif](../images/022411/022411-5/apasl7.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|